RTOG 0815 A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER

Objective

The purpose of this study is to compare the effects of dose-escalated radiation therapy with or without hormone therapy on your prostate cancer.

IRB Protocol Number

10-1101

Principal Investigator(s)

DAVID RABEN

Cancer Trials

• Prostate Cancer

Sponsor(s)

RTOG

Contact

ROBYN SWING at 720-848-0607
or ROBYN.SWING@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : Patients will receive 44 radiation treatments over approximately 2 months. With the brachytherapy implant, patients will receive 25 daily treatments plus the implant procedure over a timeframe of approximately 6 weeks. Hormone therapy, if given, will last 6 months. Patients will be followed for life. // Eligibility criteria : A screening period to determine eligibility. A treatment period (s) that can last up to (duration from ICF). A follow up period will consist of (phone contact, physician contact, or clinic visit).